祖传财产
发表于 2025-3-30 09:47:53
,The development of zileuton (ZYFLO®) and the N-hydroxyurea class of 5-lipoxygenase inhibitors,r define the biology of inflammation and allergy and provided the first new approach to asthma therapy in decades. The leukotriene research at Abbott Laboratories for the most part has concentrated on biosynthetic inhibitors, most notably the N-hydroxyurea class of inhibitors. These compounds, parti
Epidural-Space
发表于 2025-3-30 13:39:52
http://reply.papertrans.cn/67/6685/668406/668406_52.png
SPER
发表于 2025-3-30 16:37:38
The development of iralukast: A member of the Novartis series of cysteinyl leukotriene antagonists,ct by antagonizing the bronchoconstrictive, mucus secretory and inflammatory effects of these leukotrienes . Pranlukast (OnonTM, ONO-1078), zafirlukast (AccolateTM, ICI 204,219) and montelukast (SingulairTM, MK 0476) are available on the market as treatment for asthma . Further compounds,
ovation
发表于 2025-3-30 22:31:28
LTB4 receptor antagonists, on characterizing the structure and biological activities of the molecule and determining the mechanism of its biosynthesis and catabolism. Much of this research focused on the relationship between the leukotriene and neutrophils . First attempts to synthesize antagonists of the LTB. receptor
Humble
发表于 2025-3-31 04:36:16
http://reply.papertrans.cn/67/6685/668406/668406_55.png
梯田
发表于 2025-3-31 05:50:07
http://reply.papertrans.cn/67/6685/668406/668406_56.png
DEAF
发表于 2025-3-31 09:32:18
http://reply.papertrans.cn/67/6685/668406/668406_57.png
懒惰民族
发表于 2025-3-31 14:02:20
http://reply.papertrans.cn/67/6685/668406/668406_58.png
防锈
发表于 2025-3-31 19:31:14
http://reply.papertrans.cn/67/6685/668406/668406_59.png
被诅咒的人
发表于 2025-4-1 01:11:35
William T. Jacksony simplified and symmetric nonlinear models, with some notable pioneering exceptions. We hope that a Universe dominated by elementary particle relics will be largely understandable in such simple terms, and, with the COBE observation of CMB anisotropy, there is hope that our wishes will be realized.